Characteristics of Patients With <i>ROS1+</i> Cancers: Results From the First Patient-Designed, Global, Pan-Cancer <i>ROS1</i> Data Repository.

Abstract

The discovery of driver oncogenes, such as <i>ROS1</i>, has led to the development of targeted therapies. Despite clinical advancements, gaps remain in our understanding of characteristics of patients with <i>ROS1</i>-positive (<i>ROS1+</i>) cancers. The purpose of this study was to comprehensively assess demographic, clinical, and environmental characteristics associated with <i>ROS1+</i> cancers worldwide. In collaboration with a panel of patients with <i>ROS1+</i> cancer, we designed and conducted a 204-question online assessment regarding the demographic, clinical, and environmental factors of patients with <i>ROS1+</i> cancers. We invited patients with <i>ROS1+</i> cancers to participate in the study from May 2016 to December 2018. A total of 277 patients from 18 countries worldwide responded and completed at least 90% of the survey. The majority of respondents were female (n = 191; 69%), non-Hispanic white (n = 202; 73%), never-smokers (n = 180/240; 75%). Most were diagnosed with lung cancer (n = 261/277; 94%) and stage IV disease (n = 201/277; 76%). The majority received chemotherapy in first (n = 137/199; 69%) and second (n = 103/199; 52%) lines of therapy. For patients diagnosed with lung cancer after the availability of crizotinib (n = 199), only a minority (n = 55/199; 28%) reported receiving crizotinib in the first line of therapy. This study is the first global, patient-designed approach, to our knowledge, to comprehensively assess demographic, clinical, and environmental characteristics associated with <i>ROS1+</i> cancers. Future efforts include assessing these characteristics as well as patient-reported outcomes and treatment responses longitudinally.